Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

被引：4

作者：

Casulo, Carla ^{[1
]}

Dixon, Jesse G. ^{[2
]}

Ou, Fang-Shu ^{[2
]}

Hoster, Eva ^{[3
]}

Peterson, Bruce A. ^{[4
]}

Hochster, Howard S. ^{[5
]}

Brice, Pauline ^{[6
]}

Ladetto, Marco ^{[7
]}

Hiddemann, Wolfgang ^{[8
]}

Marcus, Robert ^{[9
]}

Kimby, Eva ^{[10
]}

Herold, Michael ^{[11
]}

Nielsen, Tina ^{[12
]}

Morschhauser, Franck ^{[13
]}

Rummel, Mathias ^{[14
]}

Hagenbeek, Anton ^{[15
]}

Vitolo, Umberto ^{[16
]}

Salles, Gilles A. ^{[17
]}

Shi, Qian ^{[2
]}

Flowers, Christopher R. ^{[18
]}

机构：

[1] Univ Rochester, Wilmot Canc Inst, 601 Elmwood Ave,Box 704, Rochester, NY 14642 USA

[2] Mayo Clin, Dept Biostat, Rochester, MN USA

[3] Univ Hosp Grosshadern, Munich, Germany

[4] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA

[5] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[6] Ctr Hosp Univ CHU St Louis, Paris, France

[7] Azienda Osedaliera Santi Antonio & Biagio & Cesar, Alessandria, Italy

[8] Univ Munich, Dept Hematol & Oncol, Munich, Germany

[9] Kings Coll Hosp London, London, England

[10] Karolinska Inst, Stockholm, Sweden

[11] Helios Klinikum Erfurt, Erfurt, Germany

[12] Roche, Basel, Switzerland

[13] CHU Lille, Lille, France

[14] Justus Liebig Univ, Dept Hematol, Giessen, Germany

[15] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands

[16] Fdn Piemonte Oncol, Ist Ricovero & Cura Carattere Sci FPO IRCCS, Candiolo Canc Inst, Turin, Italy

[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD ADVANCES | 2021年 / 5卷 / 06期

关键词：

D O I：

10.1182/bloodadvances.2020002724

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Limited data exist to describe the clinical features and outcomes for elderly patients with follicular lymphoma (FL). The Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) group performed a prospectively planned pooled analysis of individual patient data from first-line randomized controlled trials (RCTs) and examined associations between age (<= 70 vs >70 years), clinical characteristics, and FL outcomes. We identified 18 multicenter clinical RCTs in the FLASH database that enrolled elderly patients (>70 years). Primary end points were early disease outcomes, CR24 and CR30, and progression-free survival (PFS) at 24 months (PFS24). Secondary end points were PFS and overall survival (OS). We identified 5922 previously untreated FL patients from 18 RCTs. Patients age >70 years (vs <= 70 years) more commonly had elevated lactate dehydrogenase, hemoglobin,12 g/dL, ECOG PS >= 2, and elevated beta 2-microglobulin. Median follow-up was 5.6 years. Patients >70 years did not differ from patients <= 70 years in rates of CR24, CR30, or PFS24. With a median OS of 14.6 years for all patients, median OS was 7.4 and 15.7 years for patients >70 and <= 70 years of age, respectively (hazard ratio = 2.35; 95% confidence interval = 2.03-2.73; P < .001). Age >70 years was a significant predictor of OS and PFS due to higher rates of death without progression, but not PFS24, CR24, or CR30. FL patients >70 years treated on trials have similar early disease outcomes to younger patients. There is no disease-specific outcome difference between age groups. Age alone should not disqualify patients from standard treatments or RCTs.

引用

页码：1737 / 1745

页数：9

共 34 条

[1] Impact of age on genetics and treatment efficacy in follicular lymphoma [J].